COLY Coley Pharmaceutical Grp. (MM)

WELLESLEY, Mass., Oct. 31 /PRNewswire-FirstCall/ -- Coley Pharmaceutical Group, Inc. (NASDAQ:COLY), today announced that Robert L. Bratzler, Ph.D., Coley's President and Chief Executive Officer, plans to provide a corporate update at the upcoming the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference at 9:50am ET on November 5th, 2007 at the New York Palace Hotel. Interested parties may access an audio webcast of the presentation by visiting the Coley Pharmaceutical Group website at http://www.coleypharma.com/. A replay of the webcast will be archived on the "Investor Events" page in the Investor Center section of the Coley website for two weeks until November 19, 2007. About Coley Pharmaceutical Group Coley Pharmaceutical Group, Inc. is an international biopharmaceutical company, headquartered in Wellesley, Massachusetts, USA, that discovers and develops TLR Therapeutics(TM), a new class of investigational drug candidates that direct the human immune system to fight cancers, allergy and asthma disorders, autoimmune diseases and to enhance the effectiveness of vaccines. Coley has established a pipeline of TLR Therapeutic product candidates currently advancing through clinical development with partners and has additional product candidates in preclinical development. Coley has product development, research and license agreements with Pfizer, sanofi-aventis, GlaxoSmithKline, Merck, Novartis Vaccines and the United States government. For further information on Coley Pharmaceutical Group please visit http://www.coleypharma.com/. DATASOURCE: Coley Pharmaceutical Group CONTACT: Susan Hager, Sr. Director, Investor Relations and Corporate Communications of Coley Pharmaceutical Group, +1-781-431-9079, ; Media, Karen L. Bergman, +1-650-575-1509, , or Michelle Corral, +1-415-794-8662, , both of BCC Partners for Coley Pharmaceutical Group Web site: http://www.coleypharma.com/

Copyright